Related Experiment Video
Updated: Dec 11, 2025
Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
Targeting Smad-Mediated TGFß Pathway in Coronary Artery Bypass Graft
1Department of Veterinary Pharmacology and Toxicology, 58989Ahmadu Bello University, Zaria, Nigeria.
Insights
Targeting specific transforming growth factor-beta (TGFß) signaling pathways, particularly Smad-dependent and ALK-mediated ones, may improve outcomes for coronary artery bypass grafting (CABG) surgery by preventing intimal hyperplasia.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Surgical Innovation
Background:
- Coronary artery bypass grafting (CABG) is crucial for managing coronary heart disease (CHD).
- Over 50% of CABG surgeries fail within a decade, often due to intimal hyperplasia (IH).
- Transforming growth factor-beta (TGFß) signaling is implicated in IH, but its role is complex, with both beneficial and detrimental effects.
Purpose of the Study:
- To investigate the specific role of TGFß signaling pathways in CABG failure.
- To explore the therapeutic potential of targeting specific TGFß components, including Smad-dependent and ALK-mediated pathways, to prevent IH.
Main Methods:
- Analysis of TGFß pathway activation in human vascular smooth muscle cells (VSMCs) post-injury.
- Examination of hyperplastic changes in preimplantation vein grafts.
- Review of existing in vitro, in vivo, and clinical trial data on TGFß inhibition in CABG.
Main Results:
- TGFß signaling, particularly Smad-dependent and ALK-mediated pathways, is activated in VSMCs and vein grafts associated with IH.
- Global TGFß inhibition has shown inconsistent results, highlighting the need for targeted approaches.
- Specific components of the TGFß pathway, not the entire pathway, appear to drive vascular IH.
Conclusions:
- Focused targeting of specific Smad-dependent and ALK-mediated TGFß signaling pathways presents a promising therapeutic strategy.
- This targeted approach holds potential for improving the long-term success rates of CABG surgery by mitigating IH.
Abstract:
Revascularization surgeries such as coronary artery bypass grafting (CABG) are sometimes necessary to manage coronary heart disease (CHD). However, more than half of these surgeries fail within 10 years due to the development of intimal hyperplasia (IH) among others. The cytokine transforming growth factor-beta (TGFß) and its signaling components have been found to be upregulated in diseased or injured vessels, and to promote IH after grafting. Interventions that globally inhibit TGFß in CABG have yielded contrasting outcomes in in vitro and in vivo studies including clinical trials. With advances in molecular biology, it becomes clear that TGFß exhibits both protective and damaging roles, and only specific components such as some Smad-dependent TGFß signaling mediate vascular IH. The activin receptor-like kinase (ALK)-mediated Smad-dependent TGFß signaling pathways have been found to be activated in human vascular smooth muscle cells (VSMCs) following injury and in hyperplastic preimplantation vein grafts. It appears that focused targeting of TGFß pathway constitutes a promising therapeutic target to improve the outcome of CABG. This study dissects the role of TGFß pathway in CABG failure, with particular emphasis on the therapeutic potentials of specific targeting of Smad-dependent and ALK-mediated signaling.
